FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195156984> ?p ?o ?g. }

• W3195156984 endingPage "1073" @default.
• W3195156984 startingPage "1073" @default.
• W3195156984 abstract "Introduction: Familial hypercholesterolemia (FH) is characterized by extremely high levels of circulating low-density lipoprotein cholesterol (LDL-C) and is caused by mutations of genes involved in LDL-C metabolism, including LDL receptor (LDLR), apolipoprotein B (APOB), or proprotein convertase subtilisin/Kexin type 9 (PCSK9). Accordingly, PCSK9 inhibitors (PCSK9i) are effective in LDL-C reduction. However, no data are available on the pleiotropic effect of PCSK9i. To this end, we performed an untargeted metabolomics approach to gather a global view on changes in metabolic pathways in patients receiving treatment with PCSK9i. Methods: Twenty-five FH patients starting treatment with PCSK-9i were evaluated by an untargeted metabolomics approach at baseline (before PCSK9i treatment) and after 12 weeks of treatment. Results: All the 25 FH subjects enrolled were on maximal tolerated lipid-lowering therapy prior to study entry. After a 12 week treatment with PCSK9i, we observed an expected significant reduction in LDL-cholesterol levels (from 201.0 ± 69.5 mg/dL to 103.0 ± 58.0 mg/dL, p < 0.001). The LDL-C target was achieved in 36% of patients. After peak validation and correction, after 12 weeks of PCSK9i treatment as compared to baseline, we observed increments in creatine (p-value = 0.041), indole (p-value = 0.045), and indoleacrylic acid (p-value= 0.045) concentrations. Conversely, significant decreases in choline (p-value = 0.045) and phosphatidylcholine (p-value < 0.01) together with a reduction in platelet activating factor (p-value = 0.041) were observed. Conclusions: Taking advantage of untargeted metabolomics, we first provided evidence of concomitant reductions in inflammation and platelet activation metabolites in FH patients receiving a 12 week treatment with PCSK9i." @default.
• W3195156984 created "2021-08-30" @default.
• W3195156984 creator A5001770956 @default.
• W3195156984 creator A5004341489 @default.
• W3195156984 creator A5007516809 @default.
• W3195156984 creator A5012710359 @default.
• W3195156984 creator A5019330487 @default.
• W3195156984 creator A5021965055 @default.
• W3195156984 creator A5046517741 @default.
• W3195156984 creator A5050946951 @default.
• W3195156984 creator A5052806409 @default.
• W3195156984 creator A5064628212 @default.
• W3195156984 creator A5071743100 @default.
• W3195156984 creator A5072192699 @default.
• W3195156984 creator A5073001267 @default.
• W3195156984 date "2021-08-23" @default.
• W3195156984 modified "2023-10-10" @default.
• W3195156984 title "Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach" @default.
• W3195156984 cites W1584031633 @default.
• W3195156984 cites W1973462388 @default.
• W3195156984 cites W1981914794 @default.
• W3195156984 cites W2006466939 @default.
• W3195156984 cites W2023535481 @default.
• W3195156984 cites W2029723755 @default.
• W3195156984 cites W2035081010 @default.
• W3195156984 cites W2037773834 @default.
• W3195156984 cites W2038922520 @default.
• W3195156984 cites W2040698349 @default.
• W3195156984 cites W2045753263 @default.
• W3195156984 cites W2058217708 @default.
• W3195156984 cites W2068178193 @default.
• W3195156984 cites W2075069959 @default.
• W3195156984 cites W2079115802 @default.
• W3195156984 cites W2085615524 @default.
• W3195156984 cites W2091108957 @default.
• W3195156984 cites W2097870088 @default.
• W3195156984 cites W2100693237 @default.
• W3195156984 cites W2101185950 @default.
• W3195156984 cites W2105119801 @default.
• W3195156984 cites W2106343349 @default.
• W3195156984 cites W2111099202 @default.
• W3195156984 cites W2114991100 @default.
• W3195156984 cites W2118184073 @default.
• W3195156984 cites W2132346675 @default.
• W3195156984 cites W2146512944 @default.
• W3195156984 cites W2148858610 @default.
• W3195156984 cites W2152311269 @default.
• W3195156984 cites W2247997571 @default.
• W3195156984 cites W2317628705 @default.
• W3195156984 cites W2318576026 @default.
• W3195156984 cites W2327172638 @default.
• W3195156984 cites W2474226167 @default.
• W3195156984 cites W2520219176 @default.
• W3195156984 cites W2539904337 @default.
• W3195156984 cites W2598111690 @default.
• W3195156984 cites W2735584664 @default.
• W3195156984 cites W2744116768 @default.
• W3195156984 cites W2748800769 @default.
• W3195156984 cites W2753608024 @default.
• W3195156984 cites W2755021631 @default.
• W3195156984 cites W2759090324 @default.
• W3195156984 cites W2767490762 @default.
• W3195156984 cites W2768787369 @default.
• W3195156984 cites W2783658885 @default.
• W3195156984 cites W2791564057 @default.
• W3195156984 cites W2886217500 @default.
• W3195156984 cites W2887629426 @default.
• W3195156984 cites W2892662764 @default.
• W3195156984 cites W2894273099 @default.
• W3195156984 cites W2894417323 @default.
• W3195156984 cites W2899997727 @default.
• W3195156984 cites W2900829083 @default.
• W3195156984 cites W2910292619 @default.
• W3195156984 cites W2945439938 @default.
• W3195156984 cites W2953074494 @default.
• W3195156984 cites W2965625676 @default.
• W3195156984 cites W2989298030 @default.
• W3195156984 cites W3020215389 @default.
• W3195156984 cites W3045955397 @default.
• W3195156984 cites W3047528703 @default.
• W3195156984 cites W4205186352 @default.
• W3195156984 cites W4211262075 @default.
• W3195156984 cites W4230870013 @default.
• W3195156984 cites W4238251256 @default.
• W3195156984 cites W4249634287 @default.
• W3195156984 doi "https://doi.org/10.3390/biomedicines9081073" @default.
• W3195156984 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8391636" @default.
• W3195156984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34440277" @default.
• W3195156984 hasPublicationYear "2021" @default.
• W3195156984 type Work @default.
• W3195156984 sameAs 3195156984 @default.
• W3195156984 citedByCount "7" @default.
• W3195156984 countsByYear W31951569842021 @default.
• W3195156984 countsByYear W31951569842022 @default.
• W3195156984 countsByYear W31951569842023 @default.
• W3195156984 crossrefType "journal-article" @default.
• W3195156984 hasAuthorship W3195156984A5001770956 @default.
• W3195156984 hasAuthorship W3195156984A5004341489 @default.

• next